Idaho Psilocybin Research Pilot Study

Idaho faces one of the most urgent mental health challenges in the nation. With high rates of suicide, PTSD, and treatment-resistant depression—especially among our veteran population—and limited access to effective care, it’s time to explore new, research-based options. (click here)

Psilocybin has been granted “Breakthrough Therapy” designation by the FDA for both PTSD and treatment-resistant depression—recognizing its potential to significantly outperform existing treatments in clinical studies. (click here)

We are advocating for the creation of a time-limited psilocybin research pilot program that would allow a small, controlled group of qualified veterans to receive psilocybin-assisted therapy in a clinical research setting.

This program would:

• Serve those most at risk and least served: Idaho veterans living with PTSD or treatment-resistant depression

• Be time-limited, professionally administered, and rigorously evaluated

• Provide Idaho-specific data to help policymakers understand the potential role of psychedelic therapy in addressing our mental health crisis

This is not about recreational use or broad legalization—it’s about offering hope to those who’ve served, and gathering the evidence needed to make informed, compassionate policy decisions that put veterans’ well-being first.